ABSTRACT UDP-glucuronosyltransferase (UGT) enzymes comprise a superfamily of key proteins that catalyze the glucuronidation reaction on a wide range of structurally diverse endogenous and exogenous chemicals. Glucuronidation is one of the major phase II drug-metabolizing reactions that contributes to drug biotransformation. This biochemical process is also involved in the protection against environmental toxicants, carcinogens, dietary toxins and participates in the homeostasis of numerous endogenous molecules, including bilirubin, steroid hormones and biliary acids. Over the years, significant progress was made in the field of glucuronidation, especially with regard to the identification of human UGTs, study of their tissue distribution and substrate specificities. More recently, the degree of allelic diversity has also been revealed for several human UGT genes. Some polymorphic UGTs have demonstrated a significant pharmacological impact in addition to being relevant to drug-induced adverse reactions and cancer susceptibility. This review focuses on human UGTs, the description of the nature of polymorphic variations and their functional impact. The pharmacogenomic implication of polymorphic UGTs is presented, more specifically the role of UGT polymorphisms in modifying cancer risk and their impact on individual risk to drug-induced toxicities.
INTRODUCTION
A number of detoxifying enzymes participate in host defense against endogenous toxins and xenobiotic chemicals. Among these, the UDP-glucuronosyltransferase (UGTs; EC 2.4.1.17) enzymes are found in many diverse living organisms, from bacteria to humans. UGTs are membrane-bound conjugating enzymes that catalyze the transfer of the glucuronic acid group of uridine diphosphoglucuronic acid (UDPGlcA) to the functional group (eg hydroxyl, carboxyl, amino, sulfur) of a specific substrate (Figure 1 ). Glucuronidation increases the polarity of the target compounds and facilitates their excretion in bile or urine.
This biochemical system has been primarily studied for its role in the detoxification of exogenous compounds, mostly drugs. Indeed, virtually all classes of drugs are substrates for UGTs and this pathway has been estimated to account for approximately 35% of all drugs metabolized by phase II drugmetabolizing enzymes (DMEs). 1 At least two additional biological functions are attributed to UGTs: (i) the contribution of UGTs is determinant in the mechanism of protection against some toxic dietary components, tobacco smoke carcinogens and various environmental pollutants [2] [3] [4] [5] [6] [7] [8] [9] and (ii) they represent key elements in the homeostasis of a number of endogenous molecules, including bilirubin, steroid and thyroid hormones, fatty acids as well as biliary acids. [10] [11] [12] [13] [14] In recent years, breakthroughs in the pharmacogenomic field support the concept that genetic factors related to genes encoding DMEs, transporters and drug targets play a significant role in the clinical response to therapeutic drugs. 1, [15] [16] [17] [18] [19] These genetic factors include common genetic alterations or polymorphisms (41% frequency), small insertions or deletions, or single-nucleotide polymorphisms (SNPs). Polymorphisms are observed in various regions of a gene, including the regulatory and coding sequences, but also in the introns and the 5 0 and 3 0 untranslated regions. Depending on the nature of the variation and its location within a given gene, the phenotypic consequences may be barely noticeable, or they may alter the function or expression of the protein. In the case of UGTs, such genetic alterations would potentially modify the glucuronidation capacity of the individual carrying that polymorphism. The phenomenon is even more relevant considering that an increasing number of studies have brought to light examples of interindividual variations in the glucuronidating capacity towards various substances. 7, 16, Based on the diverse biological functions of UGTs, a significant alteration in a metabolic pathway involving these enzymes has the potential to modify significantly the pharmacokinetics of a given drug, carcinogen or endogenous molecule. Knowledge of the genetic mechanisms underlying variability in glucuronidation capacity are beginning to emerge but, to date, only a few clinically relevant genetic polymorphisms in UGTs have been described. Recent work has demonstrated that genetic variations affect glucuronidation rates and influence the risk of an individual to develop drug-induced toxicity. 35, 37, [61] [62] [63] [64] The role of genetic factors in determining variable rates of glucuronidation of hormones, tobacco smoke carcinogens, environmental pollutants and dietary components is poorly understood. Recent findings suggest that metabolic alterations may actually determine the degree of exposure of an individual to toxic or carcinogenic substances over a long time period and may contribute to modify one's susceptibility to diseases such as cancer. [65] [66] [67] [68] [69] [70] [71] [72] [73] This review is focused on recent work in the area of the pharmacogenomics of human UGTs. The following topics will be covered: (i) overview of human UGT enzymes; (ii) description of polymorphic human UGT enzymes; (iii) pharmacogenomic phenomena involving polymorphic UGT enzymes in drug response and (iv) pharmacogenomic phenomena involving polymorphic UGT enzymes in cancer.
A BRIEF OVERVIEW OF THE GLUCURONIDATION PATHWAY AND HUMAN UGTS
The glucuronidation reaction, catalyzed by membranebound UGTs, involves the transfer of the ubiquitous cosubstrate UDPGlcA to hydrophobic molecules (also called aglycones). This reaction leads to the formation of b-dglucopyranosiduronic acids or glucuronide derivatives (-G) ( Figure 1 ). The glucuronidation reaction confers polarity to xenobiotics, drugs and endogenous compounds, which are consequently more easily excreted from the body. 13 The carboxyl group from the glucuronic acid, which is ionized at physiological pH, promotes excretion by increasing the aqueous solubility of the glucuronide, otherwise highly hydrophobic. The glucuronide is recognized by the biliary and renal organic anion transport systems, which enable secretion into urine and bile. Compared to other conjugating enzymes such as acetyltransferases (NAT), glutathione Figure 1 The glucuronidation reaction. The UGTs belong to a multigene family of important enzymes involved in the inactivation and the elimination of a wide range of nucleophilic substances. UGTs conjugate both endogenous and exogenous molecules. In addition to these compounds, toxins and polycyclic and simple phenols are among the most critical substrates of transferases, although virtually all classes of drugs are substrates for UGT enzymes. UGT enzymes are localized to the internal membrane of the endoplasmic reticulum. 13 This conjugation reaction involves the transfer of the ubiquitous cosubstrate uridine diphospho-glucuronic acid (UDPGlcUA) to hydrophobic molecules (also called aglycones), leading to the formation of b-d-glucopyranosiduronic acids or glucuronide derivatives (-G). The resulting glucuronides contain the d-glucopyranuronosyl radical linked to -OR, -SR, -NR 0 R 00 or -CR. Following the glucuronidation reaction, O-glucuronide ethers are formed from substrates that contain functional groups such as aliphatic alcohols and phenols, while O-glucuronide esters are formed from substrates that contain functional groups like carboxylic acids. These are the commonest glucuronides. Glucuronidation of primary, secondary aromatic and aliphatic amines and of tertiary amines leads to the formation of N-glucuronides. In addition, the presence of a sulfhydryl functional group creates Sglucuronides, whereas carbonyl groups yield C-glucuronides, although very few examples of these derivatives have been described.
S-transferases (GST) and sulfotransferases (ST), UGTs have the most profound effect in both detoxification and promotion of excretion, via urine and bile. Furthermore, since the addition of glucuronic acid to compounds changes their structure, glucuronidation modifies the biological activity of the parent foreign compound. Generally, the biological function of the aglycone is abolished by glucuronidation. In few instances (glucuronides of morphine and retinoic acids), glucuronidation will maintain or increase their biological function. 74, 75 The knowledge about the substrate specificity of UGT enzymes and their tissue expression and regulation has progressed significantly in recent years. Although the liver is recognized as the major site of glucuronidation, it is now clear that numerous organs also have the ability to make a significant contribution to the overall glucuronidation capacity of the organism. Similar to other DMEs, UGTs are localized in all ports of entry of chemicals, including the epithelial surfaces of the nasal mucosa, the gut, skin, white blood cells and lung (reviewed in Tukey and Strassburg 76 ). UGTs are also expressed in a wide variety of tissues, including brain, prostate, uterus, breast, placenta and kidney, to name only a few. 11, [76] [77] [78] [79] [80] The molecular genetics of human UGTs is now more clearly understood, with evidence for the existence of distinct subfamilies, which comprise more than 26 genes or cDNAs (Figure 2 ). Eighteen of them correspond to functional proteins and are encoded by two gene families, UGT1 and UGT2 that are, based on their sequence similarities, further divided into three subfamilies: UGT1A, UGT2A and UGT2B (for detailed information see Mackenzie et al 81 ). In contrast to the UGT2B subfamily, which comprises several independent genes, [82] [83] [84] the entire UGT1 family is derived from a single gene locus (UGT1) spanning about 210 kb on chromosome 2 (2q37), which is composed of 17 exons. [85] [86] [87] To synthesize the final protein, only one of 13 different exon-1 sequences on the locus is associated with four downstream exons, common to all UGT1A isoforms. Of the 13 exon-1 sequences, nine code for functional proteins (UGT1A1, UGT1A3-1A10) and four correspond to pseudogenes (p) (UGT1A2p, UGT1A11p, UGT1A12p and UGT1A13p). [85] [86] [87] UGT proteins are composed of 527-530 amino-acid residues, for a molecular weight of 50-57 kDa. The exon-1 sequence of UGTs codes for the substratebinding domain (N-terminal half of the protein), while the four common exons code for the cosubstrate-binding domain (C-terminal half of the protein). The presence of different possible substrate-binding domains confers the large substrate specificity and selectivity of UGT1A proteins. The regulatory sequences flanking each of the exon-1 regions is thought to dictate the individual expression profile of the UGT1A isoforms. 76, 87 Five of the nine UGT1A isoforms were isolated from human liver, while the three remaining isoforms were observed strictly in extrahepatic tissues and demonstrated a tissue-specific expression pattern, mainly in the gastrointestinal tract. 68, [88] [89] [90] [91] [92] [93] [94] [95] To date, the structures of several UGT2B genes (composed of six exons) and cDNAs have been published. Several UGT2Bs were isolated from liver as well from extrahepatic tissues. 76, [81] [82] [83] [84] [96] [97] [98] [99] [100] [101] In addition, numerous homologous pseudogenes have been found, 83 all of which are clustered with UGT2B genes encoding functional proteins on chromosome 4 (4q13). Similar to the UGT1 family, members of the UGT2B subfamily share a high degree of similarity in the C-terminal portion of the protein and the highest degree of divergence in sequences encoded by exons 1. Two members of the UGT2A subfamily have also been characterized and are localized to chromosome 4q13. They share approximately 70% of identity with the UGT2Bs. The biological function of UGT2As was proposed to be the termination of the odorant signals, although it is not limited to this function since they are expressed in the liver, small intestine, brain and fetal lung. [102] [103] [104] The wide range of substrates for human UGTs includes compounds of diverse chemical structures. Several studies have described the overlapping substrate specificities of UGT proteins. 76, 105 On the other hand, even in the case where the homology between UGTs of the same subfamily reaches 95%, the substrate specificity of individual transferases seems to remain distinctive. More importantly, even if several UGTs share a high degree of overlapping substrate specificity, UGTs often present distinct tissue-specific expression and even cell-type-specific expression within a tissue. [88] [89] [90] 106 As an example, using a specific anti-UGT2B17 antibody, the expression of this androsterone-conjugating UGT was found exclusively in basal cells of the epithelium of the prostate. 106 Therefore, in situations where a specific UGT is inactive or less abundant, functional characteristics Figure 2 Phylogenetic tree for the different UGT isoenzymes. The dendrogram shows both UGT families that share less than 50% of homology. Percentage values represent the homology between two groups or single isoenzymes at the amino-acid level. Pseudogenes were not analyzed for homology.
Pharmacogenomics of human UGT enzymes C Guillemette of other UGTs including the specificity of an enzyme and its efficacy, tissue and cell-type-specific expression will not suffice to compensate for the deficient enzyme.
To date, a number of polymorphisms have been described for both UGT1 and UGT2B genes. This area of research has become very active and reports of polymorphic UGT genes are constantly emerging. In the following sections, human UGTs will be reviewed one by one for the presence of naturally occurring polymorphic forms of the protein, their prevalence in human populations, their functional impact and their physiological, clinical and/or pathophysiological implications.
UGT1A1
Common Polymorphisms and Rare Mutations Associated with Congenital Hyperbilirubinemia Syndromes UGT1A1 is the major UGT1 gene product that catalyzes the glucuronidation of bilirubin, a breakdown product of heme, which needs to be removed from the body. Historically, genetic defects in the UGT1 gene complex have been found to have a profound impact on the health of affected individuals, especially those modifying UGT1A1 activity. Most genetic alterations in the UGT1 gene complex that have been described to date correspond to rare mutations associated with two severe familial forms of the unconjugated hyperbilirubinemia syndromes (Crigler-Najjar type I and II disorders). Breakthroughs in the molecular genetics of these syndromes have been made with the identification of B60 rare mutations in the UGT1A1 gene, identified as point mutations, deletions and insertions (Table 1) . Only a few of these were found in the general population at a sufficiently high frequency (41%) to be classified as polymorphisms. Among these polymorphisms, there is a dinucleotide repeat in the atypical TATA-box region of the UGT1A1 promoter. Variations in the number of A(TA) n TAA repeats lead to four variant alleles (n ¼ 5 UGT1A1*33; n ¼ 6 UGT1A1*1; n ¼ 7 UGT1A1*28; n ¼ 8 UGT1A1*34) (Figure 3 ). Functional studies revealed that increasing the number of repeats in the promoter region leads to a decrease in the rate of transcription initiation of the UGT1A1 gene. 66, [107] [108] [109] The 'wild-type' allele (UGT1A1*1) contains six TA repeats, whereas the most common variant allele (UGT1A1*28) contains seven TA repeats and is associated with the mild form of the inherited unconjugated hyperbilirubinemia syndrome (Gilbert's syndrome). 109, 110 Gilbert's syndrome is also characterized by the absence of liver disease and by episodes of mild intermittent jaundice and is found in approximately 6-12% of the population. [109] [110] [111] [112] [113] Studies showed that mutations in the UGT1A1 gene, especially homozygosity for the UGT1A1*28 variant, are responsible for this syndrome. Moreover, this genetic variation of the UGT1A1 gene is a contributory factor in prolonged neonatal jaundice. [114] [115] [116] [117] A significant difference in the prevalence of the variant UGT1A1 promoter alleles has been observed. A detailed analysis of data available in the literature revealed that overall, the UGT1A1 isoform seems to be expressed at a lower level in approximately 0-3% of the Asian population, 2-13% of the Caucasian population and up to 16-19% of Africans (Table 2) . On the other hand, the UGT1A1*33 (TA 5 ) and UGT1A1*34 (TA 8 ) polymorphisms found initially in the African-American population are also observed at much lower frequencies in Caucasians. 67, 118 Although interindividual variations in UGT1A1 expression are thought to be largely because of the UGT1A1*28 polymorphism, at least one additional common polymorphic variant has been reported in the literature. A missense mutation caused the replacement of an arginine by a glycine at position 71 of the corresponding protein (UGT1A1*6 Gly 71 Arg). This mutation is predominant in Japanese and does not seem to be linked to the A(TA) 7 TAA polymorphic site. [119] [120] [121] Polymorphisms of the UGT1A1 Gene as Risk Factors for Drug-Induced Toxicity Patients affected by Gilbert's syndrome display lower glucuronidation rates for a number of therapeutic drugs including acetaminophen, tolbutamide and lorazepam. [20] [21] [22] [34] [35] [36] [37] Since Gilbert's syndrome is associated with the UGT1A1*28 (TA 7 polymorphism), it is more likely that patients with this allele will present an altered drug clearance compared to patients with the wild-type genotype. However, a correlation between the presence of variant UGT1A1 alleles and altered rates of glucuronidation has not been systematically demonstrated.
Recently, a strong correlation was observed between UGT1A1 low (UGT1A1*28) and high (UGT1A1*1) promoter activity alleles and the corresponding rates of glucuronidation of the active metabolite of irinotecan, SN-38.
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Irinotecan {CTP-11 or 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin} is an anticancer drug clinically used in combination with 5-fluorouracil and leucovorin as the first-line treatment of metastatic colorectal cancer. CPT-11 is biotransformed by carboxylesterases into a pharmacologically active metabolite, SN-38 (7-ethyl-10-hydroxycamptothecin), 123 which is responsible for severe toxicity. SN-38 undergoes significant glucuronidation to form the corresponding inactive glucuronide (10-O-glucuronyl-SN-38 (SN-38-G)) 124 and UGT1A1 isoenzyme was suggested to be the predominant human UGT involved in the formation of SN-38-G. 35 Individuals with Gilbert's syndrome are at greater risk to experience irinotecaninduced toxicity. 37 Therefore, inherited differences in irinotecan glucuronidating capacity, such as those caused by UGT1A1 promoter polymorphisms, may have an important influence on the pharmacokinetics, the pharmacologic effects and toxicity of this drug. This hypothesis is supported by the observation of an inverse relation between SN-38 glucuronidation and the severity of diarrheas occurring in patients treated with irinotecan. 122, 124 In a prospective study comprising irinotecan-treated cancer patients, the group of Iyer et al 61 observed that UGT1A1 promoter activity influences the extent of SN-38-G formation and is associated with the incidence of adverse reactions, mostly neutropenia and diarrhea. A retrospective clinical study of Japanese cancer patients revealed an association between genetic Pharmacogenomics of human UGT enzymes C Guillemette In the case of rare hyperbilirubinemia, as in CN type I, the UGT1A1*28 variant promoter does not seem to play a significant role, while in the case of CN type II, the presence of the *28 allele was shown to affect the clinical characteristics of the disease. 184, 195 In addition to being associated with elevated bilirubin plasma levels, the UGT1A1*28 allele has been linked to various diseases including glucose-6-phosphate dehydrogenase (G6PD) deficiency, neonatal jaundice, hereditary spherocytosis, cholelithiasis in children with sickle cell anemia and b-thalassemia.
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a Mackenzie et al 81 .
Pharmacogenomics of human UGT enzymes C Guillemette alterations in the promoter region of UGT1A1*28 (A(TA) 7 -TAA) and in the coding region of the UGT1A1 gene (UGT1A1*27 (Pro 229 Gln)) and the occurrence of severe irinotecan-induced toxicity. 64 The SNP present in the UGT1A1*6 (Gly 71 Arg) allele was also investigated in this study and, although this allele is highly prevalent in the Asian population, 120, 125 the presence of this polymorphism in cancer patients was not associated with irinotecaninduced toxicity. 64 This is consistent with the recent observation showing that the impact of the UGT1A1*6 allele on in vitro rates of SN-38 glucuronidation is modest compared to that observed for UGT1A1*27. 62 The hepatic UGT1A9 and the extrahepatic UGT1A7 enzymes were recently shown to be involved in the in vitro metabolism of SN-38. 62 Thus, polymorphisms in UGT1A7 and UGT1A9 along with the promoter polymorphism of UGT1A1 and functional SNPs present in its coding region, potentially represent significant risk factors for severe toxicity and could serve to predict the incidence of adverse events in patients undergoing irinotecan-based chemotherapy.
Role of UGT1A1 Variants in Estrogen-Related Cancer
The development of several cancers is modulated by steroid hormones, which are important physiological substrates of UGT enzymes. Alterations in the hormonal environment as a consequence of a change in metabolism may determine an individual's exposure over time and contribute to modify cancer risk. Several enzymes involved in the biotransformation of adrenal steroid precursors, progesterone, androgens and estrogens have been studied as candidate genes, which could potentially modify the risk of developing cancer. Inherited variations in these genes are suggested to be associated with an increased risk of developing steroidrelated cancers including breast, ovarian, endometrial and prostate cancers. The strategy for finding these low-penetrance susceptibility alleles has been the candidate gene approach, in which polymorphic variants of genes that possibly influence cancer risk are studied by conventional epidemiological studies using case-control cohorts. The UGT1 and UGT2 loci harbor putative susceptibility genes that have not been explored in detail. Recent studies revealed that specific genetic alterations in UGT genes could contribute to modify the risk factor of developing cancer. [66] [67] [68] [69] [70] [71] [72] The first series of studies were case-control studies of breast cancer patients, in which the role of UGT1A1 as a candidate gene was examined ( Table 3 ). The hypothesis tested was that constitutive alterations in UGTs involved in the inactivation of estradiol and catechol reactive metabolites could modify estrogen exposure and consequently estrogen-related cancer risk. UGT1A1 was investigated as a first candidate gene, since this UGT is expressed in human breast parenchyma and is involved in the formation of estradiol-glucuronide. 66, 126 Two genetic epidemiological studies were designed to investigate the association between genetic variability in the UGT1A1 promoter region and the risk of breast cancer: one involving African-American subjects and the other, Caucasian women. 66, 67 Based on functional studies, 66 UGT1A1 promoter alleles were divided into two classes; low transcriptional activity alleles (A(TA) 7 TAA or A(TA) 8 TAA) and high transcriptional activity alleles (A(TA) 5 TAA or A(TA) 6 TAA). It was postulated that breast cancer cases have a higher frequency of low transcriptional activity alleles (high-risk genotypes) compared to controls. An analysis of 200 African-American women with invasive breast cancer and 200 matched controls revealed that the low-activity alleles (UGT1A1*28 (A(TA) 7 TAA) and UGT1A1*34 (A(TA) 8 TAA)) were positively associated with breast cancer. 66 The pattern of results further suggested a stronger association between UGT1A1 genotype and estrogen receptor-negative breast cancer in premenopausal women. On the other hand, no significant interactions were revealed with the use of oral contraceptives or hormone replacement therapy. These findings are consistent with a role for estrogen-metabolizing UGTs in modulating the action of endogenous hormones and therefore in affecting breast cancer risk in the African-American population. This relation was further studied among 455 Caucasian women with breast cancer and 603 women without breast cancer. In this nested case-control cohort within the Nurses' Health Study, no significant risk was associated with the low transcriptional activity allele UGT1A1*28. 67 Stratification by age at menarche, menopausal status and by clinical and pathological characteristics also failed to reveal any association.
Since decreased transcription of the UGT1A1 gene has been found to be associated with increased plasma levels of other substrates metabolized by the UGT1A1 protein, such as bilirubin, the relation between the A(TA) 7 TAA allele and circulating levels of estrogens was evaluated. In postmenopausal women not using hormone replacement therapy, estrone and estradiol levels tended to vary as a function of UGT1A1 genotypes. 67 The higher plasma concentrations of estradiol and estrone found in women with the low-activity UGT allele support a role of the glucuronidation pathway in estrogen metabolism and its contribution in the maintenance of an adequate estrogenic environment in target cells. However, the elevation in the plasma levels of estrogenic hormones seems to be insufficient to alter one's risk to develop breast cancer. One can speculate that more important modifications in glucuronidation activity are needed to produce a significant alteration in breast cancer susceptibility. In fact, this situation might have been achieved in African-Americans in whom the presence of the UGT1A1*34 allele (TA 8 ) leads to a 50% decrease in the transcription of the UGT1A1 gene compared to 30% for the TA 7 allele. 66 In addition to other UGTs that potentially compensate for a deficient UGT1A1, other metabolic pathways such as sulfation could also potentially compensate for the reduced glucuronide conjugation of estrogens.
In addition, it has been suggested that catechol metabolites of estradiol contribute to the development of estrogeninduced cancers by acting as endogenous tumor initiators. 127 Alterations in glucuronidation rates could modify cancer risk by affecting the balance between estradiol and C2, C4 and C16 catechol estrogens in the target cells. The
Pharmacogenomics of human UGT enzymes C Guillemette increased formation of catechol estrogens mediated by the P450 enzymes combined with an insufficient conjugation of the estradiol and estrogen metabolites via glucuronidation might alter the risk of estrogen-related cancers. Studies on the glucuronidation of estrogenic hormones and the contribution of UGTs in altering the risk of hormone-dependent cancer need to be pursued. The role of the UGT1A1*28 allele in susceptibility to endometrial cancer is currently under evaluation.
UGT1A1 Polymorphisms and Variation in Breast Density
A recent observation supports the role of UGT1A1 in modulating the exposure of breast cells to hormones. The relation between UGT1A1 polymorphisms and breast density was investigated. 128 Premenopausal women homozygous for the UGT1A1*28 allele had significantly lower breast density compared to those with the *1/*1 genotype (À43.1% difference; P ¼ 0.04). In contrast, postmenopausal women with the UGT1A1*28/*28 genotype had greater breast density compared to those with the *1/*1 genotype (+32.0% difference; P ¼ 0.05), which was even greater among current users of postmenopausal hormone replacement therapy (+56.8% difference; P ¼ 0.03). 128 These results suggest that the UGT1A1 genotype is a predictor of breast density within groups of different menopausal status and would predict that interindividual differences in Leu allele but appears to be very rare as it was not found in two independent population studies.
Pharmacogenomics of human UGT enzymes C Guillemette estrogen glucuronidation influence breast density. Since mammographic density is one of the strongest predictors of breast cancer risk, these results would also suggest that the risk of developing breast cancer is higher in premenopausal women with the UGT1A1*28 allele and lower in postmenopausal women with the UGT1A1*28 allele. However, as described previously, the UGT1A1 genotype did not alter the risk of breast cancer in the large nested case-control study from the Nurses' Health Study, of which the Caucasian women studied in relation to breast density were a subset. Yet, it remains to be demonstrated if alterations in UGT1A1 glucuronidation rates or expression levels result in increased estrogen bioavailability within target cells. Since high levels of estrogen-glucuronides have been observed in breast cyst fluid and the expression of UGTs confirmed in estrogen target cells, formation of glucuronides within the breast, ovary and uterine tissues is expected. 66, 73 Data represent the relative risk (RR). A conditional logistic regression adjusted for the following matching variables was applied: age, menopausal status, postmenopausal hormone use, date at blood draw, time at blood draw and fasting status at blood draw. d Similar adjusted RR were observed with a conditional logistic regression adjusted for the matching variables and age at menarche, parity, age at first birth, BMI at age 18, weight gain since age 18, benign breast disease, first-degree family history of breast cancer, and duration of postmenopausal hormone use. Unconditional logistic regression adjusted for the matching variables, and age at menarche, parity, age at first birth, BMI at age 18, weight gain since age 18, age at menopause, benign breast disease, firstdegree family history of breast cancer, and duration of postmenopausal hormone use. f Matched for all variables mentioned above ( d ) and for laboratory batch.
g Based on in vitro data.
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h Genotypes were stratified according to predicted activities based on allele-encoded isozyme glucuronidating activities toward benzo[>a]pyrene metabolites (Guillemette et al. 65, 66 ). i NS=not significant. j Unconditional logistic regression was performed and adjusted for age, sex, race, region of recruitment, smoking and alcohol consumption.
k Allelic distribution followed Hardy-Weinberg equilibrium. l They were also positive for HBV surface antigen (21%), HCV RNA (26%) and diagnosed for alcoholic cirrhosis (15%). m They were also positive for HBV surface antigen (20%), HCV RNA (33%) and diagnosed for alcoholic cirrhosis (13%). n A deviation from the Hardy-Weinberg equilibrium was noted in this "control" group. Logistical regression analysis adjusted for sex. p A deviation from the Hardy-Weinberg equilibrium was noted. Allelic distribution was significantly different from the control group in Vogel et al., 69 although patients were recruited from the same geographical area.
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The Pharmacogenomics Journal UGT1A6 Common UGT1A6 Polymorphisms UGT1A6 is a phenol-metabolizing UGT, primarily involved in the glucuronidation of simple phenols and planar arylamines 5, 93 that mediates the conjugation of many currently prescribed drugs including antidepressants, neuroleptics and b-adrenoreceptor blockers. 93, [129] [130] [131] [132] [133] [134] The UGT1A6 gene has been found to be polymorphic with at least four alleles characterized by three SNPs in the coding sequence. The unmodified 'wild-type' allele is referred to as UGT1A6*1, while the allele characterized by the presence of both missense polymorphisms at codons 181 (Thr 181 Ala) and 184 (Arg 184 Ser) is referred as UGT1A6*2. 130 Although these two mutations are usually linked, both mutations have been observed separately. A single mutation at codon 184 is designated UGT1A6*3 and a single mutation at codon 181 is designated UGT1A6*4 (Table 4) . 130, 135 Functional studies by Ciotti et al 130 revealed that the protein encoded by the UGT1A6*2 allele has lower activity towards several phenolic compounds (27-75% of the rate of the wild-type enzyme). Also, 3-O-methyl-dopa and methyl salicylate were conjugated at 41-74% of the wild-type rate, whereas a series of b-blockers were metabolized at 28-69% of the normal level. The clinical implications of these variant alleles still remain to be determined. The data reported by Ciotti et al 130 has suggested that the UGT1A6*2 low-activity allele is frequent in the population (frequency of 0.173). The impact of single substitutions at codons 181 (*4) and 184 (*3) was not assessed in vitro. The allelic distribution as a function of ethnicity was further assessed in a second study conducted by Lampe et al. 135 They reported higher frequencies of the UGT1A6*2 and UGT1A6*3 alleles compared to previous studies, with distributions being slightly different between Caucasian and Asian populations (Table 4) . In a population composed of healthy Caucasian subjects (n ¼ 103), frequencies of 0.010 and 0.024 were observed for the alleles UGT1A6*3 and UGT1A6*4 and the genotype frequencies were found to be in Hardy-Weinberg equilibrium (Table 4) .
The combined distribution of polymorphisms in the TATA-box region of the UGT1A1 promoter and polymorphisms in UGT1A6 was assessed in the study of Lampe et al.
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A significant linkage disequilibrium between genotypes for UGT1A1*28 and UGT1A6*2 was observed in both Caucasian and Asian populations. Homozygous variants were observed in 8% of the cases and 43% of individuals had at least one variant allele for both UGT1A1*28 and UGT1A6*2. Therefore, for compounds metabolized by these two hepatic UGT enzymes, neither of them would theoretically be able to compensate for the deficiency of the other enzyme since low-activity UGT1A6 and UGT1A1 alleles are closely linked.
Modulation of Colon Adenoma Risk by UGT1A6 Genotypes
The group of Bigler et al 136 have explored the role of UGT1A6 polymorphic variations in relation to the risk of developing colon adenoma. In their population-based study, 474 adenoma cases and 563 control subjects were genotyped for the variations at codons 181 and 184 of UGT1A6. Regression analyses, adjusted for age, sex, smoking and hormone replacement therapy, did not reveal any significant increase in the risk of developing adenoma in subjects carrying variant UGT1A6 alleles. However, the UGT1A6 genotype was shown to modulate colon adenoma risk in aspirin users (OR ¼ 0.53 (95% CI ¼ 0.33-0.86)) and nonaspirin NSAID users (OR ¼ 0.47 (95% CI ¼ 0.24-0.92)) when compared to aspirin and nonaspirin NSAID users carrying the UGT1A6 wild-type genotype, respectively. These results suggest that the UGT genotype modulates the efficacy of chemopreventive drugs, such as NSAID.
UGT1A7
Common UGT1A7 Polymorphisms UGT1A7 metabolizes a vast panel of clinically and toxicologically important compounds. The genetic diversity of the UGT1A7 gene was revealed after resequencing the entire gene. 65 Four forms of the UGT1A7 gene product were initially found and more recently, five additional forms were discovered. There are now nine alleles of the UGT1A7 gene, which vary at the following positions: Gly 115 Ser, Asn Arg mutation. The additional genetic alterations at codons 115 and 139 were found to be less common compared to the UGT1A7*3 allele within the general population (Table 4) .
Since UGT1A7 is an important extrahepatic UGT that inactivates a variety of precarcinogens, including hydroxybenzo[a]pyrene metabolites, activities for variant UGT1A7 recombinant enzymes (*1-*4) were initially described for benzo(a)pyrene (BaP) metabolites. Functional assays were subsequently performed for UGT1A7 variant alleles *1-*9 for a variety of substrates. 65, 137 Regardless of the substrate tested, the UGT1A7 enzyme velocity was shown to be altered in the presence of polymorphisms at codons 115 and 208, regardless of the presence of the mutations affecting codons 129/131 or 139.
Role of UGT1A7 Variants in the Risk of Chemical-induced Cancers (Orolaryngeal and Lung Cancers) UGT1A7 represents one of several UGTs that were shown to conjugate chemical carcinogens. UGT1A7 has been implicated in the glucuronidation of carcinogenic metabolites of tobacco-specific nitrosamines 138, 139 and BaP. 65, 140 The expression pattern of UGT1A7 is also consistent with a role in the protection against these chemicals. UGT1A7 is expressed in extrahepatic tissues with high levels in the stomach and the esophagus, 68, 138 as well as in other tissues of the aerodigestive tract including the tongue, tonsil, floor of the mouth and larynx. 68, 141 Owing to the expression pattern of UGT1A7 and its contribution in carcinogen detoxification, the potential role of UGT1A7 in the risk of developing tobacco-related cancers, Pharmacogenomics of human UGT enzymes C Guillemette more specifically orolaryngeal cancer, was recently explored. 68 In a population-based case-control study, 125 Caucasian-American and 69 African-American subjects diagnosed with orolaryngeal cancer and 250 CaucasianAmerican and 138 African-American control subjects were genotyped for the presence of the UGT1A7*1-*4 alleles. In control subjects, the frequencies of the UGT1A7 alleles were similar to those previously reported for Caucasians and followed Hardy-Weinberg equilibrium. 65 In this study, the authors demonstrated racial differences, with the UGT1A7*2 allele occurring less frequently and the UGT1A7*3 allele occurring at a higher frequency in Caucasians compared to African-Americans. Since the isoenzymes encoded by UGT1A7*3 and *4 are significantly less active against BaPhydroxylated metabolites compared to the enzymes encoded by the *1 and *2 alleles, 65 genotypes of UGT1A7 were stratified into three categories based on their predicted phenotypes to assess the potential role of UGT1A7 alleles in the risk of developing cancer. UGT1A7*3 and *4 alleles, both containing the Arg 208 polymorphism, represented lowactivity alleles while UGT1A7*1 and *2 alleles were considered to be high-activity alleles. Unconditional regression analysis was used to account for potential confounding factors, such as sex, age, race, region of recruitment, smoking and alcohol consumption. A statistically significant increase in the risk for orolaryngeal cancer was observed among all subjects who had the predicted lowest-activity UGT1A7 genotypes compared to subjects who had the highest-activity genotypes (OR ¼ 3.7; 95% CI ¼ 1.7-7.6) ( Table 3 ). In addition, the risk was higher among African-American subjects compared to Caucasian subjects (OR ¼ 6.2, 95% CI ¼ 1.2-31 compared to OR ¼ 2.8, 95% CI ¼ 1.1-7.6). Detailed information was available for environmental exposure, which enabled the authors to assess the association between UGT1A7 genotype and the degree of exposure. Within smoking categories (light or heavy smokers), the risk for orolaryngeal cancer for subjects with predicted low-activity UGT1A7 genotypes was 8.5-to 10-fold higher compared to subjects with the predicted high-activity genotypes. These results revealed for the first time that genetic variations in the UGT1A7 gene that reduce carcinogen-detoxifying activity increase the risk of developing a smoking-related orolaryngeal cancer.
Role of UGT1A7 Variants in the Risk of Hepatocellular and Colorectal Cancers
The relation between polymorphic UGT1A7 and hepatocellular cancer (HCC) risk was investigated by Vogel et al.
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There is a strong epidemiological link between hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, liver cirrhosis and hepatocarcinogenesis. Thus, the authors included 70 Caucasian subjects with HBV and HCV infections or alcoholic cirrhosis as the 'control' population and 59 subjects with HCC. Allele frequencies were significantly different from previous studies in Caucasians and a deviation from the Hardy-Weinberg equilibrium was also evident in the control group. In this study, subjects with the UGT1A7 *1/*2 and *2/*3 genotypes were at higher risk of HCC, OR ¼ 8.46 (95% CI ¼ 2.69-26.57) and OR ¼ 7.61 (95% CI ¼ 2.08-27.84), respectively (Table 3) . Based on the biological function of the UGT1A7 alleles and taking into account the significant association between the UGT1A7*1/ *2 and *2/*3 genotypes and HCC, one would have expected the *3/*3 genotype to be associated with an increased risk of HCC. However, no association with this genotype was revealed in this study. Similarly, the UGT1A7*3/*3 allele was not associated with colorectal cancer in the study conducted by Strassburg et al, 70 although heterozygous genotypes containing the UGT1A7*3 allele (*1/*3 and *2/ *3) were associated with an approximately two-fold increased risk of developing colorectal cancer (Table 3 ). These findings were based on a case-control study composed of 210 Caucasian controls and 78 cases with colorectal cancer recruited in the same area. 70 Imbalance of the UGT1A7 genotypes was noted in the control group and allele frequencies were significantly different compared to the study of Vogel et al, 69 although subjects of both studies were recruited in the same geographical region. The rationale of studying UGT1A7 in relation with colorectal cancer is mostly based on the role of this enzyme in the metabolism and detoxification of dietary heterocyclic amines. The observation that the *3/*3 genotype is not associated with an increased risk of developing HCC and colorectal cancer is intriguing and remains unexplained.
A potential limitation in some of these studies includes the fact that confounding factors such as age, race and sex of subjects in addition to region or institution of case recruitment were often not used as matching criteria between cases and controls. For example, since patient age is a definite risk factor for colorectal cancer, controls have to be matched to cases for this criterion. Also in many of these studies, additional confounding factors including smoking status and dietary exposures were not examined in terms of gene : environment interactions. Such interactions are important factors that could potentially bias the results of risk assessment analysis of genetic variants since variability in the inherent metabolic activity of enzymes such as UGTs against environmental carcinogens is being tested in such studies. Failure to find that genotype frequencies among controls are in Hardy-Weinberg equilibrium draws attention to potential bias and caution in the interpretation of the results of the association study. 142 Optimally, population-based studies should be performed with a particular attention to these confounding factors.
Recently, a case-control study was conducted to assess the relation between characteristics of meat consumption, HCA exposure, the UGT1A7 genotype and colon cancer. A total of 400 subjects with colon cancer and 400 controls matched for age, sex and race were recruited. In this population, the allele frequencies were similar to those obtained previously. 65, 68 No main effect of the UGT1A7 genotype was observed on colon cancer risk. On the other hand, the association between dietary HCA exposure and colon cancer was increased in individuals with the low-activity UGT1A7
Pharmacogenomics of human UGT enzymes C Guillemette genotypes. 143 These data suggest that the relation between dietary sources of HCA and colon cancer may be modulated by the UGT1A7 detoxification pathway. These results also point to HCA exposure as an important etiologic factor in colon cancer.
UGT2B7
Common UGT2B7 Polymorphisms UGT2B7 is one of the most important hepatic UGTs that metabolizes a vast set of clinically, physiologically and toxicologically important compounds. The UGT2B7 protein is also found in the brain, kidney, pancreas, mammary gland, lung and gastrointestinal tract, and several additional tissues. 80, 134, 138, [144] [145] [146] A cytosine to thymine polymorphism at base pair 802, leading to a histidine (H) 268 to tyrosine (Y) amino-acid substitution (UGT2B7*2), has been identified. 147, 148 Data from large genotyping studies suggest that approximately one-third of the Caucasian population expresses the variant UGT2B7*2/*2 genotype (Table 5) . 46, 149 The prevalence of the UGT2B7*2 allele appears to be lower in Asian individuals with only 5% of the Japanese population being homozygous for the UGT2B7*2/*2 genotype (Table 5) . 46 The in vitro glucuronidation activities of the most frequent allele (UGT2B7*1) and of the UGT2B7*2 variant allele have been thoroughly investigated by different groups. 74, 147, 150 Coffman et al 74 compared both isoenzymes in the same experimental conditions using HEK 293 cell lines that stably express the *1 and *2 alleles. Reactivity towards androgenic steroids, xenobiotics, including morphinan derivatives and menthol, propranolol and oxazepam was studied. 74 Although the amino-acid change at codon 268 is a nonconservative substitution, the *2 allele (Tyr 268 ) was found to present similar catalytic properties compared to the *1 allele (His   268   ) .
No Significant Clinical Impact of the UGT2B7 Codon 268 Polymorphism Therapeutic drugs that are glucuronidated by UGT2B7 include morphine (at position 3-OH and 6-OH), zidovudine, epirubicin and carboxylic acid-containing compounds such as NSAIDS, clofibric acid and valproic acid. 134, 146, 150, 151 Functional studies suggested that the polymorphic variations in the coding region of the UGT2B7 gene do not result in variable rates of glucuronide formation and/or altered affinity of the enzyme. Thus, this polymorphism cannot account for the observed variability in biotransformation of the therapeutic drugs, which are substrates of UGT2B7 in humans.
A recent study by Holthe et al 49 failed to show that the UGT2B7 H 268 Y polymorphism is associated with a variation in the plasma ratios of morphine-3-G/morphine-6-G, morphine-3-G/morphine or morphine-6-G/morphine among cancer patients undergoing analgesic therapy with morphine, thus confirming the results of an other group.
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UGT2B7 is a major UGT responsible for the 3-and 6-glucuronidation of morphine in humans; 74, 151, 152 154 Barbier et al, 150 reported a significant difference in the ability of UGT2B7 alleles to conjugate zidovudine. The H and Y alleles had similar K m values, but a 5.6-fold higher V max was observed for the H allele compared to the Y allele. This result suggests a substrate-specific impact of this aminoacid variation. However, the clinical relevance of this polymorphism for the metabolism of zidovudine remains to be demonstrated. 150 It is clear that UGT2B7 is of major significance for the glucuronidation of a number of clinically important drugs and further studies are needed to uncover genetic variants of this gene and address their clinical effects.
Polymorphic Expression of the UGT2B7 Gene in Breast Carcinogenesis
In addition to being involved in the metabolism of a variety of xenobiotic compounds, UGT2B7 is active on endobiotics such as steroid hormones including androgens, estrogens, pregnanes, biliary acids and retinoic acids. [146] [147] [148] 151, 155 Recently, the expression of UGT2B7 was demonstrated in normal human breast parenchyma and in invasive and in situ breast cancers. 73 A previous study reported that the glucuronidation activity was lower in breast cancer specimens compared to normal tissues. 156 Using a specific anti-UGT2B7 antibody, Gestl et al 73 demonstrated that UGT2B7 is expressed in the epithelium lining the mammary gland ductal system with variable intensities between individuals. A variation in the expression of UGT2B7 among epithelial cells of the same tissue was also observed. In cancer cells, the staining within invasive lesions was virtually absent while in situ lesions presented a high level of UGT2B7 expression. In the same study, the levels of 4-hydroxyestrone glucuronidating activity were also assessed in normal tissues from mammoplastic surgeries and in normal and cancerous tissues from neoplastic specimens. The glucuronidation rate of estrogen was significantly lower in neoplastic tissues compared to normal tissues, which is consistent with UGT2B7 expression data. The authors suggested an antineoplastic function of the UGT2B7 within the mammary gland based on its role in the conjugation of estrogens and retinoic acids. Interestingly, because of the increased in situ expression of UGT2B7 in neoplastic foci, a preinvasive stage of carcinogenesis, a defense mechanism involving Pharmacogenomics of human UGT enzymes C Guillemette For the genotype frequency, the 12% difference represents all the other genotypes (*1/*6, *1/*7, *1/*8, *2/*6, *2/*7, *2/*8, *2/*9, *2/*10, *3/*6, *3/*7, *4/*7, *5/*5 and *5/*9). Alleles are defined in Figure 2 .
g Guillemette et al, unpublished data. reported such a cell-type-specific expression of UGT2B enzymes in the human prostatic tissue. The role of UGT2B7 polymorphisms in relation to breast cancer risk has not been reported.
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UGT2B15
Common UGT2B15 Polymorphisms UGT2B15 is involved in the inactivation of steroid hormones, mainly androgens, and also displays a glucuronidating activity toward several classes of xenobiotic substrates, including simple phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones and other drugs and their hydroxylated metabolites. 96, 97, 153, 157 A G-T substitution at codon 85 results in an amino-acid change (Asp 85 Tyr) within the putative substrate recognition site of UGT2B15. A number of population genotyping studies were completed to characterize the distribution of UGT2B15*1 and *2 alleles among individuals of distinct ethnic background (Table 5 ). UGT2B15*1 is less frequent in Caucasians compared to other populations (Asian, Hispanic and African). Overall, homozygous subjects for the variant *2 allele were found in 19-32% of the population. The functional impact of UGT2B15 polymorphisms on enzyme activity was studied in vitro using intact cells (in situ assays) and microsomal preparations. These analyses revealed that the UGT2B15*2 allele presents similar K m values and approximately two-fold different V max values for androgens (dihydrotestosterone (DHT)) and androstane-3alpha,17beta-diol (3a-Diol)) in in situ cell assays. 96 In a recent investigation, the catalytic properties of UGT2B15 variants were assessed with cellular fractions of the same HEK 293 cells. The conjugating activity of the UGT2B15*1 allele for Soxazepam was five-fold higher than that of UGT2B15*2. 153 As suggested by the authors, these differences could reflect differential stabilities of UGT2B15 proteins under the experimental conditions used for microsome preparation as opposed to enzymatic assays in intact cells. 96, 153 Nevertheless, the role of UGT2B15 in the interindividual variability in S-oxazepam glucuronidation remains to be determined in vivo. Of interest, an additional polymorphic site was also reported at codon 86 adjacent to the 85 polymorphism (Figure 3 ). The function of this polymorphism has not been studied yet. 158, 159 Potential Role of the UGT2B15 Gene in the Risk of Developing Prostate Cancer Among the androgen-metabolizing UGT2B enzymes, namely UGT2B28, UGT2B15 and UGT2B17, UGT2B15 is the most efficient UGT2B enzyme involved in the metabolism of the main metabolite of DHT, namely 3a-Diol. 144 Variations in androgen levels have been associated with the risk of developing prostate cancer. Since UGT2B15 plays an important role in the metabolism of androgens in target tissues such as the prostate, differences in the activity of this androgen-inactivating enzyme could result in a modified degree of exposure of prostate cells to DHT.
Two independent epidemiological studies have determined the potential role of the UGT2B15 gene in relation to prostate cancer risk (Table 5) . 71, 72 The first study described the prevalence of variant UGT2B15 alleles in a case-control population of 64 patients with pathologically confirmed prostate cancer and 64 controls recruited in the state of Arkansas. 72 102 UGT1A8 demonstrates a high reactivity towards numerous endogenous and exogenous substrates including dietary and environmental carcinogens and drugs. 2, 90, 160, 161 A recent study has shown that at least three alleles of the UGT1A8 gene exist: UGT1A8*1, the most frequent allele; UGT1A8*2, with a mutation at codon 173 (Gly 173 Ala) and UGT1A8*3, bearing an amino-acid change at codon 277 (Cys 277 Tyr). 162 These variants were discovered after resequencing exon-1 from UGT1A8 in a population of 69 individuals. The observed frequencies were 0.55 (*1), 0.15 (*2) and 0.02 (*3). The altered function of variant UGT1A8 proteins was assessed by transfection of the corresponding cDNAs in HEK 293 cells to examine the catalytic activity on substrates such as hydroxybenzo[a]pyrene metabolites and a number of additional simple phenols. Similar catalytic properties were observed for the UGT1A8*1 and *2 alleles, whereas the tyrosine at codon 277 in UGT1A8*3 led to an inactive protein. At this time, the clinical impact of a polymorphic UGT1A8 allele such as the relatively rare UGT1A8*3 remains to be elucidated.
UGT2B4
UGT2B4 plays a role in the metabolism of bile acids and detoxification of many phenols. 98, 144, 148, 155, [163] [164] [165] [166] [167] [168] [169] UGT2B4 is expressed in the liver and in a wide range of extrahepatic Pharmacogenomics of human UGT enzymes C Guillemette tissues. 98, 144 One common polymorphism has been found in the UGT2B4 gene and the resulting variant allele is designated as UGT2B4 Asp 458 Glu (UGT2B4*2). 98 The single amino-acid change from aspartate to glutamate at codon 458 is located in the putative cosubstrate binding domain. The UGT2B4*2 allele is found at a frequency varying between 0.17 and 0.38 in the Caucasian, African and Hispanic populations, while it is absent from the Asian population. 98, 101, 149 The minor amino-acid change at codon 458 is unlikely to alter rates of glucuronidation. This assumption is based on in vitro data, which suggest no functional impact of the variation at position 458 on gene product function when assessed with bile acids, phenol derivatives and catecholestrogens as substrates. 98 An additional cDNA clone isolated from human liver corresponds to the UGT2B4 Phe 109 Leu, Phe 396 Leu allele 165 and appears to be very rare as it was not found in 272 individuals that were genotyped in two independent studies. 98, 149 99 UGT2B28 demonstrated much lower intrinsic clearances (V max /K m ) towards multiple steroid molecules compared to UGT2B15 and UGT2B17. Differential tissue expression profiles of two truncated UGT2B28 variants (types II and III) probably resulting from exon skipping, has been reported. 99 UGT2B28 type II differs from type I by a deletion of 308 bp (103 amino acids) in the cofactor-binding domain, whereas UGT2B28 type III lacks 351 bp (117 amino acids) in the putative substrate-binding domain. The expression of active UGT2B28 type I protein was limited to the breast and liver, as well as to the prostatic cell line LNCaP. The biological function of the shorter UGTB28 isoforms has yet to be elucidated.
CONCLUDING REMARKS
In summary, a high degree of interindividual variability in the glucuronidation rates of numerous compounds has been described. While genetic polymorphism is a possible cause for such phenotypic variations, alterations in glucuronidation activity may be related to age, gender, disease, diet or environmental influences. Additional studies are needed to elucidate and characterize polymorphic UGTs to promote the understanding of interindividual variations in the glucuronidation metabolic pathway, their pharmacological and toxicological importance, and their role in cancer susceptibility. Much research in this area is needed although promising leads have emerged, especially regarding the role of UGT genetic polymorphisms in cancer etiology and on their possible implication in modulating the degree of exposure to several carcinogenic compounds. Additional well-designed case-control population-based studies are needed to generalize these results. Special attention would need to be accorded to the detailed assessment of exposure in further investigations.
